PSA screening for prostate cancer reduces disease-specific deaths, new review shows
-
By
-
Annalisa Merelli
-
May 15, 2026
-
Clinical Scorecard: New review indicates that PSA screening for prostate cancer may lower mortality rates associated with the disease
At a Glance
| Category | Detail |
|---|
| Condition | Prostate Cancer |
| Key Mechanisms | PSA screening identifies high levels of prostate-specific antigen as a potential marker of prostate cancer. |
| Target Population | Men, particularly those at higher risk for prostate cancer. |
| Care Setting | Primary care and urology settings. |
Key Highlights
- PSA screening may reduce prostate cancer mortality by about 2 deaths per 1,000 men screened.
- Moderate certainty in the benefits of PSA screening based on a review of six trials with 800,000 participants.
- Need for careful patient selection to minimize risks of overdiagnosis and overtreatment.
- Long-term data supports the role of PSA screening in reducing disease-specific deaths.
- Improved methods for biopsy selection are now available to enhance screening effectiveness.
Guideline-Based Recommendations
Diagnosis
- Consultation with a physician is essential before PSA testing.
Management
- Regular monitoring of PSA levels is recommended for those screened.
Monitoring & Follow-up
- Ongoing patient-physician relationships are crucial for interpreting PSA results.
Risks
- Potential for overdiagnosis and overtreatment, especially in low-grade cancers.
Patient & Prescribing Data
Men at risk for prostate cancer, particularly those with elevated PSA levels.
Screening should be accompanied by informed discussions about potential risks and benefits.
Clinical Best Practices
- Utilize biomarkers and imaging to refine biopsy decisions.
- Encourage ongoing patient engagement and follow-up for effective screening outcomes.
- Educate patients about the limitations and benefits of PSA screening.
Related Resources & Content
